New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF-7 Cancer Cells

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Gallego-Jara J, Lozano-Terol G, Sola-Martínez RA, Cánovas-Díaz M, de Diego Puente T. A compressive review about taxol: History and future challenges. Molecules. 2020;25(24):1–24. doi:10.3390/molecules25245986
   Web of Science ®Google Scholar
• Haggag Y, Abu Ras B, El-Tanani Y, et al. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells. Expert Opin Drug Deliv. 2020;17(11):1655–1669.
   PubMed Web of Science ®Google Scholar
• Haggag YA, Yasser M, Tambuwala MM, El Tokhy SS, Isreb M, Donia AA. Repurposing of Guanabenz acetate by encapsulation into long-circulating nanopolymersomes for treatment of triple-negative breast cancer. Int J Pharm. 2021;600:120532.
   PubMed Web of Science ®Google Scholar
• Wani MC, Taylor HL, Wall ME, Coggon P, McPhail A. Plant antitumour agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent agent from Taxus brevifolia. J Am Chem Soc. 1971; 93:2325–2327.
   PubMed Web of Science ®Google Scholar
• Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, et al.Insights into the mechanism of microtubule stabilization by Taxol. Proc Natl Acad Sci USA. 2006;103(27):10166–10173. doi:10.1073/pnas.0603704103
   PubMed Web of Science ®Google Scholar
• Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):1–24. doi:10.3390/ijms21093233
   Web of Science ®Google Scholar
• Saloustros E, Mavroudis D, Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother. 2008;9(15):2603–2616. doi:10.1517/14656566.9.15.2603
   PubMed Web of Science ®Google Scholar
• Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22(47):7280–7295. doi:10.1038/SJ.ONC.1206934
   PubMed Web of Science ®Google Scholar
• Liverani C, De Vita A, Spadazzi C, et al. Lineage‐specific mechanisms, and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture. Mol Oncol. 2022;16(4):921–939.
   PubMed Web of Science ®Google Scholar
• Luo X, Wang G, Wang Y, et al. Gibberellin derivative GA-13315 overcomes multidrug resistance in breast cancer by up-regulating BMP6 expression. Front Pharmacol. 2022;13:1059365.
   PubMed Web of Science ®Google Scholar
• Długosz A, Janecka A. ABC transporters in the development of multidrug resistance in cancer therapy. Curr Pharm Design. 2016;22:4705–4716. doi:10.2174/1381612822666160302103646
   PubMed Web of Science ®Google Scholar
• Cabral F. Mechanisms of resistance to drugs that interfere with microtubule assembly. The Role of Microtubules in Cell Biology. Neuro Oncol. 2008;2008:337–356.
   Google Scholar
• Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther. 2006;5(2):270–278. doi:10.1158/1535-7163.MCT-05-0190
   PubMed Web of Science ®Google Scholar
• Wang Y, Yin S, Blade K, Cooper G, Menick DR, Cabral F. Mutations at Leucine 215 of β-tubulin affect paclitaxel sensitivity by two distinct mechanisms. Biochemistry. 2006;45(1):185–194. doi:10.1021/bi051207d
   PubMed Web of Science ®Google Scholar
• Yin S, Bhattacharya R, Cabral F. Human mutations that confer paclitaxel resistance. Mol Cancer Ther. 2010;9(2):327–335. doi:10.1158/1535-7163.MCT-09-0674
   PubMed Web of Science ®Google Scholar
• Myers AJ, Pittman AM, Zhao AS, et al.The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007;25(3):561–570. doi:10.1016/j.nbd.2006.10.018
   PubMed Web of Science ®Google Scholar
• Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA. 2005;102(23):8315–8320. doi:10.1073/pnas.0408974102
   PubMed Web of Science ®Google Scholar
• Berruti A, Bitossi R, Gorzegno G, et al. Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines. Br J Cancer. 2005;92(4):634–638. doi:10.1038/sj.bjc.6602335
   PubMed Web of Science ®Google Scholar
• Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem. 2012;287:29075–87.
   PubMed Web of Science ®Google Scholar
• Pięta M, Kędzia J, Kowalczyk D, Wojciechowski J, Wolf WM, Janecki T. Enantioselective synthesis of 5-methylidenedihydrouracils as potential anticancer agents. Tetrahedron. 2019;75:2495–2250. doi:10.3390/molecules25030611
   Web of Science ®Google Scholar
• Długosz-Pokorska A, Drogosz J, Pięta M, et al. New uracil analogs with exocyclic methylidene group as potential anticancer agents. Anticancer Agents Med Chem. 2020;20(3):359–368. doi:10.2174/1871520619666191211104128
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63. doi:10.1016/0022-1759(83)90303-4
   PubMed Web of Science ®Google Scholar
• Winer J. Development and validation of real-time quantitative reverse transcriptase–polymerase chain reaction for monitoring gene expression in cardiac myocytesin vitro. Anal Biochem. 1999;41–49. doi:10.1006/abio.1999.4085
   PubMed Web of Science ®Google Scholar
• Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3):e00149. doi:10.1002/prp2.149
   PubMed Web of Science ®Google Scholar
• Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Medic. 2015;13(1):2–13. doi:10.1186/s12916-015-0439-8
   PubMedGoogle Scholar
• Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotech. 2019;7(1):3–23. doi:10.2174/2211738507666190122111224.
   PubMedGoogle Scholar
• Sun Y, Kumar P, Sodani K, et al. Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncol Rep. 2014;31(4):1605–1612. doi:10.3892/or.2014.3002
   PubMed Web of Science ®Google Scholar
• Motiwala MN, Rangari VD. Combined effect of paclitaxel and piperine on an MCF-7 breast cancer cell line in vitro: Evidence of a synergistic interaction. Synergy. 2015;2(1):1–6. doi:10.1016/j.synres.2015.04.001
   Google Scholar
• Tian W, Liu J, Guo Y, Shen Y, Zhou D, Guo S. Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells. J Mater Chem. 2015;3(7):1204–1207. doi:10.1039/c4tb01633e
   Web of Science ®Google Scholar
• Yang X, Shen J, Gao Y, et al. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P‐glycoprotein and enhancing apoptosis. Int J Cancer Res. 2015;137(8):2029–2039. doi:10.1002/ijc.29574
   Web of Science ®Google Scholar